# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹1,484 Cr** H1 FY'26 (+42%) · **₹758 Cr** Q2 FY'26 (+46%) * **EBITDA:** **₹453 Cr** H1 FY'26 (+118%) · **₹246 Cr** Q2 FY'26 (+129%) * EBITDA Margin: **30.5%** H1 FY'26 (+210 bps) · **32.5%** Q2 FY'26 (+250 bps) * **PAT:** **₹266 Cr** H1 FY'26 (+141%) · **₹148 Cr** Q2 FY'26 (>2x) ## B. Revenue Growth * **Broad-Based Momentum:** Robust top-line expansion driven by strong demand across all business segments and operating leverage from scale-up. * **Growth Drivers:** Revenue surge underpinned by volume growth, favorable pricing, product mix, and efficiency gains. ## C. EBITDA & Margins * **Margin Acceleration:** Significant EBITDA margin expansion reflecting operating leverage, with disciplined cost control despite rising sub-sourcing expenses. * **Cost Dynamics:** Employee costs declined while operating costs rose only modestly (12%), amplifying margin gains; forex benefits offset by input cost pressures. ## D. Profit After Tax * **Bottom-Line Surge:** PAT more than doubled in both H1 and Q2, tracking ahead of revenue and EBITDA growth due to improved operating performance and tax efficiency. ## E. Balance Sheet * **Strong Financial Position:** Company maintains a healthy balance sheet with conservative leverage and working capital days well within target framework. --- # 2. Order Book & Demand ## A. Key Figures * **R32 Peak Annual Revenue Potential:** **INR 600–825 Cr** (projected) * **Global ex-China HFC Capacity:** **300,000–350,000 tonnes** (current) * **ex-China HFC Demand Growth:** **~5% CAGR** (current and projected) ## B. CDMO Order Visibility * **Sustained Momentum:** All three business verticals show strong growth in Q2 FY'26, underpinned by a healthy order book signaling continued strength into H2 FY'26 and beyond. * **Execution on Track:** Fermion fulfilling existing orders on schedule despite new plant not yet operational, reflecting robust operational resilience. * **Strategic Scaling:** CDMO vertical maintains strong order visibility, progressing toward the **INR 100 Cr top-line aspiration**. ## C. HPP & Specialty Demand * **Margin Expansion Drivers:** Volume growth is the primary contributor to improved EBITDA margins, accounting for approximately three-quarters of the year-on-year improvement across all verticals. * **Cost Discipline:** Focus on lowering variable costs and enhancing operational efficiencies in utilities and manufacturing processes supports sustainable margin enhancement. ## D. R32 Market Demand * **Balanced Monetization Strategy:** R32 project designed to maximize realization via a mix of offtake agreements and open market sales, with commissioning targeted for Q3 FY'27. * **Favorable Market Dynamics:** Tight supply-demand balance persists globally, with healthy demand growth in Western markets and rising domestic adoption supporting a stable export-domestic mix. * **No Near-Term Imbalance Expected:** Current capacity and demand trends suggest a well-aligned market, with exports remaining a key growth vector in line with industry patterns. --- # 3. Capacity & Utilization ## A. Key Figures * **R32 Capex:** **₹236.5 Cr** for **15,000 MT/year HFC capacity** (peak revenue **₹600–825 Cr/yr**) * **MPP Debottlenecking Capex:** **₹75 Cr** at Dahej (peak revenue **₹140–160 Cr/yr**) * **AHF Commissioning Target:** **Q3 FY'26** · **MPP Ramp-up:** **Q3 FY'27** ## B. R32 Capacity Expansion * **Strategic R32 Scale-up:** New capacity leverages Kigali-Montreal entitlements and rising global demand for low-GWP refrigerants amid ex-China supply constraints. * **Market Positioning:** Incremental R32 output to be balanced between committed and open markets, ensuring full quota utilization without oversupply risk. * **Demand Tailwinds:** Expansion driven by structural growth in RAC and blend markets, with no new Indian HFC capacity permitted post-2026. ## C. MPP Debottlenecking * **Asset Optimization Focus:** MPP upgrade enhances value creation and realization, not dedicated to any single product (e.g., Novel AI), supporting partnerships with global innovators. * **Near-Term Commercialization:** Fermion’s facility commissioned ahead of schedule; commercial supply expected in January, aligning with ramp-up timeline. * **CDMO Capacity Adequacy:** No current constraints in CDMO operations—short-cycle projects effectively managed. ## D. HF & AHF Utilization * **Long-Term HF Strategy:** Underutilization intentional; HF platform designed for high-value downstream derivatives, not merchant volume. * **Value-over-Volume Approach:** Focus on maximizing realization per kg via electronic grade HF, advanced materials, and specialty chem partnerships. * **Full Utilization Path:** HF and R32 capacities expected to reach full ramp-up by **2029–2030**, aligned with strategic downstream development. --- # 4. Product & Segment Performance ## A. Key Figures * **CDMO Revenue:** **₹134 Cr** Q2 FY'26 (+98%) · **~50%** H1 growth * **Specialty Chemicals Revenue:** **₹220 Cr** Q2 FY'26 (+39% from ₹158 Cr) * **HPP Revenue:** **>₹400 Cr** Q2 FY'26 (+38%) ## B. CDMO Segment Growth * **Accelerated Momentum:** CDMO revenue nearly doubled YoY, driven by strong demand and execution, with robust order book supporting H2 outperformance targets. * **Strategic Partnerships Advancing:** European MSA collaboration progressing, with commercial supplies set to begin January 2026 from cGMP4 facility, underpinning scalability. * **Nectar on Track:** Performance slightly exceeds midpoint of PAR, approaching ₹300 Cr target from anchor customer despite regulatory delays having no revenue impact. * **Sustainable Growth Focus:** Management emphasizes scalable, long-term CDMO value creation over near-term revenue milestones, including aspirational $100M+ target. ## C. Specialty Chemicals * **Capacity Ramp-Up Complete:** Fluoro specialty plant operating at optimum levels since December 2024, driving strong volume-led revenue growth. * **R32 Demand Resilient:** Expansion supported by structural tailwinds—direct use, blends, exports (due to Western consumption cuts), and rising domestic adoption. * **New Plant Clarity Pending:** Purpose of ₹75 Cr specialty facility—potential link to Novel AI or commercial product—awaits further disclosure. ## D. Agri & HPP Performance * **HPP Delivers Strong Growth:** Revenue surpassed ₹400 Cr on 38% YoY growth, reflecting effective market penetration and operational strength. * **Agri Innovation Pipeline Deepening:** Closer ties with global innovators enhancing R&D access, supporting debottlenecking and future product development. --- # 5. Customer & Partnership Progress ## A. Key Figures *No significant quantitative financial metrics available for extraction.* ## A. Global Innovator Ties * **Strategic R&D Focus Yields Firm Orders:** Deepening alliances with global innovators secured a firm manufacturing order for a key intermediate tied to a novel AI application in CY '26. * **Late-Stage Molecule Momentum Builds:** Successful delivery of a new late-stage molecule to a major EU client sets stage for a repeat order in CY '26, with readout expected by year-end. * **High-Potential Pipeline Expansion:** Repeat order pipeline includes a molecule with **potential to become another Fermion**, underscoring strategic value of current CDMO engagements. * **Innovative Agrochemical Breakthrough:** New agrochemical intermediate is a novel herbicide with significant growth potential, reflecting expanded innovation footprint. ## B. Strategic Customer Audits * **CDMO Credibility Reinforced by Major Pharma Audits:** Three new audits by large pharmaceutical companies validate quality systems and signal strong commercial interest in late-stage molecule capabilities. * **Digital Manufacturing Enables Real-Time Partner Integration:** Advanced process control and **BCS systems** enable real-time monitoring of quality and performance, shared with global partners to strengthen trust and collaboration. * **cGMP4 Site Validation on Track:** Six-month approval timeline driven by rigorous batch validation for new site and circuit; progress remains aligned with plan. ## C. MSA & Co-Development Talks * **Advanced Materials Vertical in Development:** Robust pipeline with agro and advanced materials partners includes CRO and scale-up campaigns, supporting creation of a dedicated new business segment. * **Long-Term Supply Stability Secured:** Existing long-term arrangements for R32 ensure contractual sales visibility with global players. * **Strategic Partnerships Evolving Beyond Supply:** Ongoing discussions with **Honeywell and other key customers** on multi-product baskets; while no capex decisions finalized, engagement reflects deepening strategic alignment. * **Pipeline Diversification Accelerating:** Addition of **two new products** to supply pipeline beyond Fermion expands future scale potential. --- # 6. Pricing & Supply Risks ## A. R32 Pricing Stability * **Pricing Outlook:** Constructive view on R32 pricing stability for CY '26 and medium term, supported by demand outpacing supply growth, with new capacity largely confined to India. * **Contract Strategy:** Midterm contracts structured as **win-win arrangements** to maintain pricing close to prevailing market levels, reinforcing long-term customer partnerships. * **Margin Protection:** Company committed to **strategically nurturing R32** to preserve margin integrity across domestic and export markets. ## B. China Supply Cuts * **Supply Tightening Ahead:** R32 supply constraints expected to intensify, with **10% production cuts forecast in China by 2029**, followed by Western markets and India (from 2032). * **Minimal Tariff Impact:** Tariff effects on operations remain negligible, rated **2–3 out of 10**, with no material disruption to date. ## C. Contract vs Spot Mix * **Balanced Sales Approach:** Management maintains a **measured mix of contract and spot sales**, aligned with capacity expansion and demand dynamics, though exact proportions not disclosed. * **Long-Term Contracting:** R32 midterm agreements typically span **4 to 5 years**, underscoring strategic, relationship-driven market positioning. --- # 7. Guidance & Outlook ## A. Key Figures * **Capex Outflow (FY26):** **₹600–700 Cr** expected, with **₹300 Cr** spent in H1 * **Project Timeline:** **Full facility utilization** targeted by **FY27 (Mar '27)** · **Chemours Opteon project** on track for **Q1 FY27 completion** ## B. FY26 Margin Target * **Confident Margin Upside:** Management sees more upside than downside to the **30% EBITDA margin target**, underpinned by strong recent performance and operational discipline. * **Medium-Term Focus:** Targeting structurally higher margins near **30%**, with FY27 expectations to crystallize closer to FY26 end. ## C. Capex & Revenue Trajectory * **Self-Funded Growth:** All capex fully funded through **internal accruals**, supporting brownfield-led operating leverage beyond FY27. * **Strategic Asset Utilization:** Growth driven by **disciplined investments** and **sweating existing assets**, with value-accretive projects set to accelerate revenue post-FY27. ## D. FY27 Growth Visibility * **High Visibility into CY26:** Strong order book supports optimism for H2 and beyond, including **repeat order expected in CY26** and **readout by Nov/Dec 2025** for potential expansion. * **Peak Revenue Inflection:** **European MSA molecule** expected to reach peak revenue in **FY27**, with significant demand runway extending to **2029**, de-risking capacity investments.